{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:47Z","timestamp":1761498527927,"version":"build-2065373602"},"reference-count":122,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.beha.2021.101330","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T14:03:25Z","timestamp":1635170605000},"page":"101330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in polycythemia vera and lessons for acute leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Jerry L.","family":"Spivak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7037","key":"10.1016\/j.beha.2021.101330_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.beha.2021.101330_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.beha.2021.101330_bib3","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2021.101330_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"16","key":"10.1016\/j.beha.2021.101330_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2021.101330_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood.V92.1.4.413k38_4_10","article-title":"Role of c-mpl in early hematopoiesis","volume":"92","author":"Solar","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101330_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01254-w","article-title":"Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?","author":"Spivak","year":"2021","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2021.101330_bib9","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2021.101330_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2021.101330_bib11","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","article-title":"Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden","volume":"4","author":"Karantanos","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.beha.2021.101330_bib12","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"issue":"4","key":"10.1016\/j.beha.2021.101330_bib14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/leu.2014.20","article-title":"The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2021.101330_bib15","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2015-01-621110","article-title":"Molecular insights into regulation of JAK2 in myeloproliferative neoplasms","volume":"125","author":"Silvennoinen","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood-2006-06-029769","article-title":"Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years","volume":"109","author":"Gale","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib18","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2013.08.007","article-title":"Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells","volume":"154","author":"Yamamoto","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.beha.2021.101330_bib20","first-page":"419","article-title":"Myeloproliferative disorders: usefulness of X-linked probes in diagnosis","volume":"3","author":"Taylor","year":"1989","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0002-9343(96)00351-8","article-title":"Inapparent polycythemia vera: an unrecognized diagnosis","volume":"102","author":"Lamy","year":"1997","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib22","first-page":"144","article-title":"Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies","volume":"23","author":"Ellis","year":"1986","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.beha.2021.101330_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2018834044","article-title":"How I treat polycythemia vera","volume":"134","author":"Spivak","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/sj.leu.2404908","article-title":"Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?","volume":"22","author":"Cassinat","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib26","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3324\/haematol.2018.213108","article-title":"Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values","volume":"104","author":"Silver","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De S","year":"2018","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.beha.2021.101330_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V126.23.484.484","article-title":"MPL SV, a unique MPN MPL splice variant, provokes a fulminant myeloid leukemia in a JAK2 V617F transgenic mouse model of polycythemia vera","volume":"126","author":"Spivak","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2021.101330_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","article-title":"Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells","volume":"1","author":"Qian","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib30","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.3707","article-title":"Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion","volume":"20","author":"Bruns","year":"2014","journal-title":"Nat Med"},{"issue":"7470","key":"10.1016\/j.beha.2021.101330_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12495","article-title":"Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy","volume":"502","author":"Sanjuan-Pla","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.beha.2021.101330_bib32","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101330_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2021.101330_bib35","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood-2014-02-558015","article-title":"JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101330_bib36","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1182\/blood.V88.8.2859.bloodjournal8882859","article-title":"Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro","volume":"88","author":"Borge","year":"1996","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2021.101330_bib37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2007.10.020","article-title":"Thrombopoietin\/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche","volume":"1","author":"Yoshihara","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.beha.2021.101330_bib38","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood.V89.10.3544","article-title":"Thrombopoietin does not induce lineage-restricted commitment of Mpl-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation","volume":"89","author":"Goncalves","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.183.2.651","article-title":"Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin","volume":"183","author":"de Sauvage","year":"1996","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.beha.2021.101330_bib40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood.V98.4.1019","article-title":"Thrombocytopenic c-mpl(-\/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response","volume":"98","author":"Levin","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22927","article-title":"Congenital amegakaryocytic thrombocytopenia","volume":"57","author":"Geddis","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0042-6822(86)90125-X","article-title":"MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice","volume":"149","author":"Wendling","year":"1986","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib43","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.V88.2.402.bloodjournal882402","article-title":"A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation","volume":"88","author":"Yan","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib45","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib46","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis","volume":"35","author":"Williams","year":"2007","journal-title":"Exp Hematol"},{"issue":"31","key":"10.1016\/j.beha.2021.101330_bib47","doi-asserted-by":"crossref","first-page":"11444","DOI":"10.1073\/pnas.0404241101","article-title":"Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis","volume":"101","author":"Moliterno","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.2008.07430.x","article-title":"Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene","volume":"144","author":"El Harith","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ng0198-49","article-title":"An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia","volume":"18","author":"Wiestner","year":"1998","journal-title":"Nat Genet"},{"issue":"17","key":"10.1016\/j.beha.2021.101330_bib50","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2010-06-290718","article-title":"Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis","volume":"116","author":"Posthuma","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2021.101330_bib51","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2008-04-149047","article-title":"The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2021.101330_bib52","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera","volume":"338","author":"Moliterno","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2021.101330_bib53","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/blood.V90.10.4031","article-title":"Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia","volume":"90","author":"Horikawa","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2141.2000.02430.x","article-title":"The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia","volume":"111","author":"Li","year":"2000","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.beha.2021.101330_bib55","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V94.8.2555.420k14_2555_2561","article-title":"Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera","volume":"94","author":"Moliterno","year":"1999","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2021.101330_bib56","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1182\/blood-2011-08-372524","article-title":"Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes","volume":"119","author":"Pecquet","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0002-9343(98)00090-4","article-title":"Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis","volume":"104","author":"Wang","year":"1998","journal-title":"Am J Med"},{"issue":"6384","key":"10.1016\/j.beha.2021.101330_bib58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.aap8861","article-title":"Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance","volume":"360","author":"Decker","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.beha.2021.101330_bib59","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2021.101330_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232801","article-title":"Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera","volume":"15","author":"Spivak","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.beha.2021.101330_bib61","first-page":"790","article-title":"Physiopathology and course of Polycythemia vera as related to therapy","volume":"142","author":"Dameshek","year":"1950","journal-title":"J Mec Appl"},{"issue":"132","key":"10.1016\/j.beha.2021.101330_bib62","first-page":"499","article-title":"Polycythemia vera: clinical studies on a series of 127 patients managed without radiation therapy","volume":"33","author":"Perkins","year":"1964","journal-title":"Q J Med"},{"issue":"7","key":"10.1016\/j.beha.2021.101330_bib63","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101330_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.0954-6820.1950.tb10111.x","article-title":"Polycythemia vera. Course and prognosis","volume":"138","author":"Videbaek","year":"1950","journal-title":"Acta Med Scand"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib65","first-page":"483","article-title":"The treatment of polycythemia. A panel discussion","volume":"32","author":"Wasserman","year":"1968","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2021.101330_bib66","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.1984.tb01283.x","article-title":"The 'spent' phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis","volume":"56","author":"Najean","year":"1984","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2021.101330_bib68","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.bi.48.070179.001025","article-title":"Reduction of ribonucleotides","volume":"48","author":"Thelander","year":"1979","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib69","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V90.2.597","article-title":"Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor","volume":"90","author":"Shimoda","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2021.101330_bib70","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2015.07.650","article-title":"Evolving therapeutic options for polycythemia vera: perspectives of the Canadian myeloproliferative neoplasms group","volume":"15","author":"Sirhan","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.beha.2021.101330_bib71","first-page":"1","article-title":"Stepping out of antiquity: an update on emerging drugs for the treatment of polycythemia vera","author":"Castillo Tokumori","year":"2021","journal-title":"Expet Opin Emerg Drugs"},{"issue":"4403","key":"10.1016\/j.beha.2021.101330_bib72","first-page":"143","article-title":"A clinical lecture on erythremia","volume":"171","author":"Osler","year":"1908","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib73","first-page":"291","volume":"7","author":"Harrop","year":"1928","journal-title":"Polycythemia. Medicine."},{"key":"10.1016\/j.beha.2021.101330_bib74","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1172\/JCI102643","article-title":"The use of K42 or P32 labeled erythrocytes and I131 taggd human serum albumin in simultaneous blood volume determinations","volume":"31","author":"Berson","year":"1952","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2021.101330_bib75","first-page":"13","article-title":"The control of polycythemia by marrow inhibition","volume":"141","author":"Lawrence","year":"1949","journal-title":"J Mec Appl"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib76","first-page":"488","article-title":"The case for phlebotomy in polycythemia vera","volume":"32","author":"Dameshek","year":"1968","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib77","first-page":"206","article-title":"Wasserman and the history of polycythemia vera","volume":"62","author":"Berlin","year":"1995","journal-title":"Mt Sinai J Med"},{"issue":"8","key":"10.1016\/j.beha.2021.101330_bib78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"8102","key":"10.1016\/j.beha.2021.101330_bib79","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(78)92098-6","article-title":"Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia","volume":"2","author":"Pearson","year":"1978","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2021.101330_bib80","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2021.101330_bib81","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1172\/JCI102339","article-title":"Iron metabolism hematopoiesis following phlebotomy iron as a limiting factor","author":"Finch","year":"1950","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.beha.2021.101330_bib82","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00005792-198211000-00004","article-title":"Non-hematologic effects of chronic iron deficiency. A study of patients with polycythemia vera treated solely with venesections","volume":"61","author":"Rector","year":"1982","journal-title":"Medicine (Baltim)"},{"issue":"23","key":"10.1016\/j.beha.2021.101330_bib83","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2021.101330_bib84","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2021.101330_bib85","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/bloodadvances.2019000822","article-title":"Response to meta-analysis of leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera","volume":"3","author":"Ronner","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib86","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2141.1982.tb01900.x","article-title":"Uncontrolled thrombocytosis in chronic myeloproliferative disorders","volume":"50","author":"Kessler","year":"1982","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2021.101330_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 Years without high-risk features","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib89","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"91995","key":"10.1016\/j.beha.2021.101330_bib90","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","author":"Gruppo Italiano","year":"1995","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib91","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1016\/j.beha.2021.101330_bib92","first-page":"1973","article-title":"DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia","volume":"51","author":"Jain","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.beha.2021.101330_bib93","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2007-07-103267","article-title":"Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance","volume":"110","author":"Antonioli","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib94","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/10428194.2016.1213833","article-title":"Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone","volume":"58","author":"Verger","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib95","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"3065","key":"10.1016\/j.beha.2021.101330_bib96","first-page":"3072","article-title":"Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in Polycythemia Vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2021.101330_bib97","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2021.101330_bib98","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa0906695","article-title":"Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009","volume":"361","author":"Jain","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2021.101330_bib99","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101330_bib100","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","article-title":"Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes","volume":"96","author":"Stein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2021.101330_bib101","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib102","first-page":"129","article-title":"The relationship of polycythemia vera to leukemia; a critical review","volume":"4","author":"Schwartz","year":"1950","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.beha.2021.101330_bib103","first-page":"305","article-title":"Polycythemia vera and leukemia - the role of radiation treatment","author":"Modan","year":"1965","journal-title":"Medicine; 1965"},{"issue":"12","key":"10.1016\/j.beha.2021.101330_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030401","article-title":"Impaired DNA replication within progenitor cell pools promotes leukemogenesis","volume":"3","author":"Bilousova","year":"2005","journal-title":"PLoS Biol"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib105","first-page":"1049","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2021.101330_bib106","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1073\/pnas.98.3.1036","article-title":"p53 accumulates but is functionally impaired when DNA synthesis is blocked","volume":"98","author":"Gottifredi","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib107","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larran","year":"2016","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.beha.2021.101330_bib108","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib109","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2021.101330_bib110","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3324\/haematol.2018.195289","article-title":"Evolutionary trajectory of leukemic clones and its clinical implications","volume":"104","author":"Tuval","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI94518","article-title":"Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms","volume":"128","author":"Zhao","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"306","key":"10.1016\/j.beha.2021.101330_bib113","doi-asserted-by":"crossref","first-page":"306fs38","DOI":"10.1126\/scitranslmed.aac4428","article-title":"Aging as a driver of leukemogenesis","volume":"7","author":"McKerrell","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib114","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajhg.2017.05.013","article-title":"Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life","volume":"101","author":"Acuna-Hidalgo","year":"2017","journal-title":"Am J Hum Genet"},{"issue":"14","key":"10.1016\/j.beha.2021.101330_bib115","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2021.101330_bib116","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"7540","key":"10.1016\/j.beha.2021.101330_bib117","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"50","key":"10.1016\/j.beha.2021.101330_bib118","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"10.1016\/j.beha.2021.101330_bib119","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.beha.2021.101330_bib120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/1097-0142(19880101)61:1<89::AID-CNCR2820610115>3.0.CO;2-0","article-title":"Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up","volume":"61","author":"Najean","year":"1988","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2021.101330_bib121","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"90","author":"Najean","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2021.101330_bib122","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/0008-5472.CAN-09-1212","article-title":"The high mobility group A1 gene: transforming inflammatory signals into cancer?","volume":"70","author":"Resar","year":"2010","journal-title":"Cancer Res"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:05Z","timestamp":1761498425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521692621000955"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101330","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in polycythemia vera and lessons for acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101330"}}